CLINICAL TRIALS PROFILE FOR AMPHETAMINE SULFATE
✉ Email this page to a colleague
All Clinical Trials for AMPHETAMINE SULFATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00218348 ↗ | Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2003-09-01 | Dextro-amphetamine sulfate is a central nervous system stimulant that increases the release of the neurotransmitter dopamine in the brain. The purpose of this study is to further examine dose ranges of dextro-amphetamine sulfate as a treatment for cocaine dependence. |
| NCT00218348 ↗ | Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo | Completed | The University of Texas Health Science Center, Houston | Phase 2 | 2003-09-01 | Dextro-amphetamine sulfate is a central nervous system stimulant that increases the release of the neurotransmitter dopamine in the brain. The purpose of this study is to further examine dose ranges of dextro-amphetamine sulfate as a treatment for cocaine dependence. |
| NCT00248092 ↗ | Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse | Completed | New River Pharmaceuticals | Phase 1/Phase 2 | 2006-01-01 | This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. NRP104 is an investigational drug. This means that it has not been approved by the U.S. Food and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss. |
| NCT00715520 ↗ | Neurobiological Principles Applied to the Rehabilitation of Stroke Patients | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | N/A | 2007-04-01 | The purpose of this study is to use (Transcranial Magnetic Stimulation) TMS or drugs to improve learning of movement skills and the adaptation processes in patients after stroke. Once investigators have determined the improving effect of TMS and the drugs on learning of movement skills, the study team may be able to provide information that improves rehabilitative treatment and helps to improve recovery after stroke. |
| NCT00715520 ↗ | Neurobiological Principles Applied to the Rehabilitation of Stroke Patients | Completed | National Institutes of Health (NIH) | N/A | 2007-04-01 | The purpose of this study is to use (Transcranial Magnetic Stimulation) TMS or drugs to improve learning of movement skills and the adaptation processes in patients after stroke. Once investigators have determined the improving effect of TMS and the drugs on learning of movement skills, the study team may be able to provide information that improves rehabilitative treatment and helps to improve recovery after stroke. |
| NCT00715520 ↗ | Neurobiological Principles Applied to the Rehabilitation of Stroke Patients | Completed | Emory University | N/A | 2007-04-01 | The purpose of this study is to use (Transcranial Magnetic Stimulation) TMS or drugs to improve learning of movement skills and the adaptation processes in patients after stroke. Once investigators have determined the improving effect of TMS and the drugs on learning of movement skills, the study team may be able to provide information that improves rehabilitative treatment and helps to improve recovery after stroke. |
| NCT01986062 ↗ | Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting | Completed | Arbor Pharmaceuticals, Inc. | Phase 4 | 2013-12-01 | This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in approximately 100 pediatric patients (aged 6 to 12 years) with ADHD. Eligible patients will enroll to take open-label AR11 BID and undergo dose optimization activities for 8 weeks. Patients who achieve a stable dose during the dose optimization period will continue participation and will be randomized to take double-blind medication (AR11 or placebo) orally twice daily for 1 week. At the end of each double-blind treatment period, patients will be evaluated for ADHD symptoms in a laboratory classroom setting utilizing SKAMP and PERMP assessments. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMPHETAMINE SULFATE
Condition Name
Clinical Trial Locations for AMPHETAMINE SULFATE
Trials by Country
Clinical Trial Progress for AMPHETAMINE SULFATE
Clinical Trial Phase
Clinical Trial Sponsors for AMPHETAMINE SULFATE
Sponsor Name
